The present application relates to the use of a substance that regulates BCL11A
gene and / or its encoded product in the preparation of a
drug for reversing
skin photoaging, wherein the
skin photoaging includes
skin cell aging caused by
sunlight, light, etc., and the skin cells include keratinocytes, dermal fibroblasts, melanocytes. The regulation is to up-regulate the expression of BCL11A
gene and / or promote the production of its encoded product. Typical clinical manifestations of the
skin photoaging include wrinkles,
dry skin,
loose skin, dilated capillaries, uneven skin pigmentation, and
skin itching. The substance that regulates BCL11A
gene and / or its encoded product includes a substance that regulates BCL11A gene
DNA molecules and a substance that regulates the expression of BCL11A translation product
protein molecules. The reversal of
skin photoaging is manifested in reducing the proportion of cells positive for aging-related beta-galactosidase
staining in skin cells and reducing the expression of aging-related
protein p16 and
DNA damage
protein gammaH2AX.